Process for preparing intermediates to florfenicol
3 claims: 1 independent, 2 dependent
- 1A process for producing florfenicol ([R-'R*, S*)]-2,2,-dichloro-N-(1-(fluoramethyl)-2-hydroxy-2-[4-methylsulfonyl) phenyl]ethyl]acetamide), which comprises:(a) preparing a compound of formula (I): wherein R is and R'' is aryl, halo aryl benzyl, substituted benzyl, C 1 to C 8 alkyl, C 3 to C 7 cycloalkyl, and haloalkyl, and the configuration of the oxazoline ring is 4R trans by contacting a compound of formula II: wherein R is as described above, and R' is H, C 1 to C 6 alkyl, C 3 to C 7 cycloalkyl, benzyl, substituted benzyl, or aryl;with a reducing agent in a protic solvent, in a suitable reaction vessel, to obtain a compound of formula III: wherein R is as described above, (b) then in the same reaction vessel reacting said compound of formula III, with a compound of the formula IV: R"-C=N (IV) to obtain a compound of the formula I, and (c) converting said compound of formula (I) to florfenicol.
- 2A process according to Claim 1 wherein the compound of formula that is formed is:
- 3A process according to Claim 1 wherein the compound for formula I that is formed is:
Independent claims3
26 paragraphs in 7 sections, as filed
FIELD OF THE INVENTION
0001The present invention relates to a novel process for preparing florfenicol.
BACKGROUND OF THE INVENTION
0002Florfenicol, also known as [R-(R*, S*)]-2,2-Dichloro-N-[1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]acetamide, is a broad spectrum antibacterial agent useful in the treatment of gram positive, gram negative and rickettsial infections as disclosed in <patcit id="pcit0001" dnum="US4361557A"><text>U. S. Patent 4,361,557</text></patcit> which is hereby incorporated by reference. The present invention relates to intermediates to florfenicol and to a novel process for preparing them. The intermediates described in the present specification can be used to prepare florfenicol as can be seen, for example, in <patcit id="pcit0002" dnum="US4876352A"><text>US Patent 4,876,352</text></patcit>, which is hereby incorporated by reference.
SUMMARY
0003The present invention is directed toward a process for producing florfenicol ([R-(R*, S*)]-2,2,-dichloro-N-[1-(fluoromethyl)-2-hydroxy-2-[4-methylsulfonyl)phenyl]ethyl]acetamide), which comprises: <ul id="ul0001" list-style="none"><li>preparing a compound of formula (I): <chemistry id="chem0001" num="0001"><img file="EP0922040B2_D0001.tif" /></chemistry></li><li>wherein R is CH<sub>3</sub>SO<sub>2</sub>,and R" is aryl, halo aryl, benzyl, substituted benzyl, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, and haloalkyl, and the configuration of the oxazoline ring is 4R trans:</li><li>which comprises contacting a compound of formula II: <chemistry id="chem0002" num="0002"><img file="EP0922040B2_D0002.tif" /></chemistry></li><li>wherein R is as described above, and R' is H, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, benzyl, substituted benzyl or aryl; with a reducing agent such as potassium borohydride, in a protic solvent in a suitable reaction vessel, to obtain a compound of formula III: <chemistry id="chem0003" num="0003"><img file="EP0922040B2_D0003.tif" /></chemistry></li><li>wherein R is as described above, then in the same reaction vessel reacting a compound of formula III, with a compound of the formula IV: R"―C≡N IV wherein R" is as described above so as to obtain compound of the formula I, and converting said compoud of formula (I) to florfenicol.</li></ul>
0004The present invention has the advantage of being an efficient and economical process for preparing florfenicol and oxazoline intermediates thereto.
DETAILED DESCRIPTION OF THE EMDODIMENTS
0005When utilized in the present specification and in the appended claims, the terms listed hereinbelow, unless otherwise indicated, are defined as follows:
0006The term "protic solvent" is intended to mean hydrogen-bonding solvent, as defined in <nplcit id="ncit0001" npl-type="b"><text>James B. Hendrickson, Cram, Donald J., and Hammond, George S., Organic Chemistry, Mcgraw Hill Book Company, New York, New York, (1970), 1279 pp</text></nplcit>. The solvent should preferably, but not necessarily, be capable of precipitating oxazoline (I) out of solution. Such solvents include, but are not limited to, water, C<sub>1</sub> to C<sub>10</sub> alkanoic acids such as formic acid, acetic acid and the like, C<sub>1</sub> to C<sub>10</sub> alcohols such as methanol and ethanol and mixtures thereof, C<sub>2</sub> to C<sub>10</sub> dialcohols such as ethylene glycol and C<sub>1</sub> to C<sub>10</sub> trialcohols such as glycerin. Alternatively, the protic solvent can be admixed with any suitable cosolvent in order to effect precipitation of oxazoline compound (I). Such cosolvents can include other protic solvents which are miscible with the protic solvent such as C<sub>4</sub> to C<sub>10</sub> alkanes, aromatic solvents such as benzene, toluene, xylenes, halobenzenes such as chlorobenzene, and ethers such as diethylether, tert-butytmethylether, isopropylether and tetrahydrofuran, or mixtures of any of the above solvents or cosolvents.
0007The term "alkyl" means a straight or branched alkyl such as methyl, ethyl, propyl, or sec-butyl. Alternatively, the number of carbons in alkyl may be specified. For example, C<sub>1</sub> to C<sub>6</sub> alkyl means an alkyl as described above containing 1 to 6 carbon atoms. "Haloalkyl" means an "alkyl" as described above wherein one or more hydrogens are replaced by halo.
0008The term "aryl" means phenyl, or phenyl substituted by C<sub>1</sub> to C<sub>6</sub> alkyl or halo.
0009Substituted benzyl means benzyl substituted by C<sub>1</sub> to C<sub>6</sub> alkyl, or halo.
0010The term "halo" means fluoro, chloro, bromo, or iodo.
0011The term "halo aryl" means phenyl substituted by halo.
0012In the present specification, <chemistry id="chem0004" num="0004"><img file="EP0922040B2_D0004.tif" /></chemistry> which is an aminodiol sulfone, is referred to as ADS.
0013The procedure for preparing florfenicol includes the following steps : <chemistry id="chem0005" num="0005"><img file="EP0922040B2_D0005.tif" /></chemistry> wherein R, R' and R" are as described herein.
0014With reference to the formula scheme above, a compound of formula I may be prepared as follows. A compound of formula II <chemistry id="chem0006" num="0006"><img file="EP0922040B2_D0006.tif" /></chemistry> wherein R and R' are as described above is treated with a reducing agent such as NaBH<sub>4</sub>, Ca(BH<sub>4</sub>)<sub>2</sub>, LiBH<sub>4</sub> or more preferably KBH<sub>4</sub> in a protic solvent such as ethanol, ethylene glycol, or more preferably methanol, at a temperature in the range of about 0 °C to about 30 °C more preferably room temperature for a period of about 2 to about 8 hours, more preferably about 4 hours to obtain a compound of formula III: <chemistry id="chem0007" num="0007"><img file="EP0922040B2_D0007.tif" /></chemistry> wherein R is as described above.
0015If, for example, in the reaction described just above, methanol is employed as the solvent in the reduction, it may be recovered by distillation for reuse in subsequent reactions. Removing methanol can also improve the yield of the compound of formula I.
0016In the same reaction vessel, the compound of formula III is contacted with a compound of formula IV, R<sup>a</sup>-C≡N IV wherein R" is as described above, in the amount of about 1.1 to about 2.5 equivalents, preferably about 1.7 equivalents as compared to the compound of formula III.
0017Compounds of formula IV can be, for example, benzonitrile or dichloroacetonitrile. The reaction is run at a temperature between 25°C and 115°C depending upon the nitrile and the solvent employed. The reaction is run from about 6 hours to about 30 hours, preferably 18 hours. The reaction mixture is then cooled, for example, by the addition of cold water and worked up by conventional means such as filtration and washing to afford a compound of formula I. Preferably this step of the reaction is run at a pH in a range of about 6 to about 7.
0018An advantage of the present process is that it eliminates the need to isolate ADS, since both reaction steps are run in the same vessel.
0019Formation of the dichloromethyl oxazoline is preferred and the formation of the phenyl oxazoline is most preferred.
0020The serine ethyl ester, as shown below, is the preferred starting material of formula II. <chemistry id="chem0008" num="0008"><img file="EP0922040B2_D0008.tif" /></chemistry>
0021The following examples illustrate the present invention in a manner by which it can be practiced but, as such, should not be construed as limitations on the scope of the invention.
EXAMPLE 1
0022<chemistry id="chem0009" num="0009"><img file="EP0922040B2_D0009.tif" /></chemistry>
0023KBH<sub>4</sub> (1g) is placed in about 40 mL of methanol. D-Threo p-methylsulfonyl phenyl serine ethyl ester (5 g) is added with stirring. The reduction to ADS is complete in several hours and can be monitored by HPLC. When the reaction is complete, 20 mL of glycerin is added to destroy any excess reducing agent and methanol is removed by distillation. After the methanol has been removed, the resulting mixture is heated to 105 °C and benzonitrile (3.1 mL) is added while continuing heating for about 18 hours. Formation of the desired oxazoline can be monitored by HPLC. The reaction is cooled to room temperature and worked up by addition of cold water, filtration of the resulting solids, washing of the solids with methanol then drying under vacuum. The yield is about 4.7 g (81 %) of material that is identical to an authentic sample of the phenyl oxazoline.
EXAMPLE 2
0024<chemistry id="chem0010" num="0010"><img file="EP0922040B2_D0010.tif" /></chemistry>
0025KBH<sub>4</sub> (1 g) is placed in about 40 mL of methanol. D-Threo p-methylsulfonylphenyl serine ethyl ester (5 g) is added with stirring. The reduction to ADS is complete in several hours and can be monitored by HPLC. When the reaction is complete, 20 mL of glycerin is added to destroy any excess reducing agent and methanol is removed by distillation. After the methanol has been removed, the resulting mixture is acidified to a pH of about 6 to 7 with H<sub>2</sub>SO<sub>4</sub> and dichloroacetonitrile (2.4 g) is added. The reaction is stirred at 50°C for about 18 hours. Formation of the desired oxazoline can be monitored by HPLC. The reaction is cooled to room temperature and worked up by filtration of the solids, washing of the solids with isopropanol and 2 % NaHCO<sub>3</sub> then drying under vacuum. The yield is about 3.8 g (65 %) of material that is identical to an authentic sample of the dichloro oxazoline.
THE STARTING MATERIALS
0026The starting materials of formula (II) and (IV) are known to those skilled in the art.
Contents7
26 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US4876352A | Cites | United States of America | Opposition |
| US5382673A | Cites | United States of America | Opposition |
| WO9014434A1 | Cites | World Intellectual Property Organization (WIPO) | Opposition |
| EP0130633A2 | Cites | European Patent Office (EPO) | – |
| WO9002739A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9014434A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9207824A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| US2759001A | Cites | United States of America | – |
| US4361557A | Cites | United States of America | – |
| US4876352A | Cites | United States of America | – |
| US5382673A | Cites | United States of America | – |
| CUTLER ET AL.: 'Synthesis', 1991, JON E. CLARK ET AL., BLOOMFIELD pages 891 - 894 | Non-patent | – | – |
| DORIS, P. SCHUMACHER: 'J. Org. Chem.', vol. 55, 1990, AMERICAN CHEMICAL SOCIETY pages 5291 - 5294 | Non-patent | – | – |
| CUTLER ET AL.: "Synthesis", 1991, JON E. CLARK ET AL., BLOOMFIELD, pages: 891 - 894 | Non-patent | – | Opposition |
| DORIS, P. SCHUMACHER: "J. Org. Chem.", vol. 55, 1990, AMERICAN CHEMICAL SOCIETY, pages: 5291 - 5294 | Non-patent | – | Opposition |
55 members in 31 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 699271 | United States of America | – | |
| 69927196 | United States of America | A | |
| 9714205 | United States of America | W |
Members55
| Document | Office | Kind | |
|---|---|---|---|
| US5663361A | United States of America | A | |
| CO4560550A1 | Colombia | A1 | |
| ZA977406B | South Africa | B | |
| ID18047A | Indonesia | A | |
| CA2264116A1 | Canada | A1 | |
| WO9807709A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU4063897A | Australia | A | |
| PE99798A1 | Peru | A1 | |
| NO990756D0 | Norway | D0 | |
| NO990756L | Norway | L | |
| TR199900354T2 | Türkiye | T2 | |
| EP0922040A1 | European Patent Office (EPO) | A1 | |
| CZ54099A3 | Czechia | A3 | |
| PL331644A1 | Poland | A1 | |
| BR9711318A | Brazil | A | |
| CN1233244A | China | A | |
| NZ334111A | New Zealand | A | |
| HK1017890A1 | Hong Kong, China | A1 | |
| AR008298A1 | Argentina | A1 | |
| AU714495B2 | Australia | B2 | |
| IL128574D0 | Israel | D0 | |
| TW381075B | Taiwan Province of China | B | |
| JP2000501424A | Japan | A | |
| SK19999A3 | Slovakia | A3 | |
| HU9904166A2 | Hungary | A2 | |
| HUP9904166A2 | Hungary | A2 | |
| KR20000068178A | Republic of Korea | A | |
| KR100286851B1 | Republic of Korea | B1 | |
| HU9904166A3 | Hungary | A3 | |
| HUP9904166A3 | Hungary | A3 | |
| JP3274868B2 | Japan | B2 | |
| IL128574A | Israel | A | |
| CA2264116C | Canada | C | |
| NO312962B1 | Norway | B1 | |
| CN1097583C | China | C | |
| MY115679A | Malaysia | A | |
| EP0922040B1 | European Patent Office (EPO) | B1 | |
| AT283847T | Austria | T | |
| ATE283847T1 | Austria | T1 | |
| DE69731835D1 | Germany | D1 | |
| PT922040E | Portugal | E | |
| SI0922040T1 | Slovenia | T1 | |
| DK0922040T3 | Denmark | T3 | |
| ES2234026T3 | Spain | T3 | |
| DE69731835T2 | Germany | T2 | |
| CZ297915B6 | Czechia | B6 | |
| PL196454B1 | Poland | B1 | |
| SK286124B6 | Slovakia | B6 | |
| TR200800474T2 | Türkiye | T2 | |
| PL198553B1 | Poland | B1 | |
| BR9711318B1 | Brazil | B1 | |
| EP0922040B2This record | European Patent Office (EPO) | B2 | |
| ES2234026T5 | Spain | T5 | |
| DE69731835T3 | Germany | T3 | |
| HU229610B1 | Hungary | B1 |
102 legal events, as 16 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expiredExpiredMK9A | MK9A | IE | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Expiry of rightR071 | R071 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Ep patent no longer valid in the republic of lithuaniaMM9D | MM9D | LT | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Discontinued in the netherlands as no translation has been filedVDEP | VDEP | NL | |
| Deletion acc. to par. 5 (withdrawal of the translation of the ep patent)MK05 | MK05 | AT | |
| Patent application has lapsedLapsedNAV | NAV | SE | |
| Patent discontinued in portugalMP4A | MP4A | PT | |
| Patent modifiedDC2A | DC2A | ES | |
| Epo decision maintaining patent in amended form now finalR102 | R102 | DE | |
| Maintained in amend formAELC | AELC | CH | |
| Patent maintained in amended form27A | 27A | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Epo decision maintaining patent in amended form now finalR102 | R102 | DE | |
| Change of applicant/patenteeR081 | R081 | DE | |
| Change of applicant/patenteeR081 | R081 | DE | |
| Change of representativeR082 | R082 | DE | |
| Change of representativeR082 | R082 | DE | |
| Patent maintained in amended formORIGINAL CODE: 0009272PUAH | PUAH | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA | STAA | EP | |
| Change of name or company nameCD | CD | FR | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Change of the firm name or firm addressHC | HC | AT | |
| Change of data on ownerSP73 | SP73 | SI | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Transfer of patentPC2A | PC2A | ES | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Modifications of names of proprietors of patentsTD | TD | NL | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Party data changed (patent owner data changed or rights of a patent transferred)RAP2 | RAP2 | EP | |
| Name/firm changedPFA | PFA | CH | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Examination report in opposition despatched + time limitOppositionORIGINAL CODE: EPIDOSNORE2PLAY | PLAY | EP | |
| Reply to examination report in opposition receivedOppositionORIGINAL CODE: EPIDOSNORE3PLBC | PLBC | EP | |
| Examination report in opposition despatched + time limitOppositionORIGINAL CODE: EPIDOSNORE2PLAY | PLAY | EP | |
| Appeal procedure closedAppealORIGINAL CODE: EPIDOSNNOA9OAPBU | APBU | EP | |
| Observations filed by third partiesORIGINAL CODE: EPIDOSNTIPATPAC | TPAC | EP | |
| Date of receipt of statement of grounds of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA3OAPBQ | APBQ | EP | |
| Name/firm changedPFA | PFA | CH | |
| Appeal reference modifiedAppealORIGINAL CODE: EPIDOSCREFNOAPAH | APAH | EP | |
| Date of receipt of notice of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA2OAPBP | APBP | EP | |
| Communication despatched that patent is revokedRevokedORIGINAL CODE: EPIDOSNREV1RDAF | RDAF | EP | |
| Observations filed by third partiesORIGINAL CODE: EPIDOSNTIPATPAC | TPAC | EP | |
| Reply of patent proprietor to notice(s) of opposition receivedOppositionORIGINAL CODE: EPIDOSNOBS3PLBB | PLBB | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Fr: translation filedET | ET | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX | PLAX | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Standard patents granted in hong kongGrantedGR | GR | HK | |
| Ep patent validated in greeceEP | EP | GR | |
| Translation of granted ep patentGrantedTRGR | TRGR | SE | |
| Translation is availableAVAILABILITY OF NATIONAL TRANSLATIONSC4A | SC4A | PT | |
| New agentNV | NV | CH | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP |
Numbers
- Publication
- 0922040
- Application
- 979382637
Titles3
- German
- VERFAHREN ZUR HERSTELLUNG VON ZWISCHENPRODUKTEN DES FLORFENICOLS
- English
- PROCESS FOR PREPARING INTERMEDIATES TO FLORFENICOL
- French
- PROCEDE DE PREPARATION D'INTERMEDIAIRES DU FLORFENICOL
Classification
- CPC, 2
- C07D263/28
- C07D263/02
- IPC, 2
- C07D263 28
- C07D263 14
Designated states21
- Contracting states, 17
- Austria
- Belgium
- Switzerland
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Portugal
- Sweden
- Extension states, 4
- Lithuania
- Latvia
- Romania
- Slovenia
